Bexion Pharmaceuticals, Inc. Represented at 15 th Annual BioNetwork Partnering Summit

National Cancer Institute (NCI) S elects Bexion as a Presenting Company

FOR IMMEDIATE RELEASE

Covington, KY ~ October 1 8 , 201 8 – Bexion Pharmaceuticals, Inc., a clini cal stage biotechnology company focused on developing innovative cures for cancer, announce s that Dr. Ray Takigiku, Founder and CEO of the Company presented recently at the 15 th Annual BioNetwork Partnering Summit, held in Laguna Nigel, CA from October 10 – 12, 2018. Chosen by the National Cancer Institute as part of its SBIR Investor Initiatives program, Bexion was among a select group of companies th at the N CI sponsored to present at this annual biotech industry financial partnering forum.

Over 200 se nior decision makers in pharma and biotech deal making attend ed the conference to pursue relationships for partnerships and investment opportunities.

Dr. Takigiku presented the Bexion story to the audience and participated in numerous one to one meetings with pharma organizations.

About NCI SBIR Investor Initiatives Program

Through the Investor Initiatives Program, the National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Development Center connects NCI SBIR funded companies wi th potential investors and strategic partners to continue the research and commercialization efforts initially funded by NCI. Companies must apply and are selected by a panel of independent experts including over 50 Venture Capital organizations and potent ial strategic partners.

About Bexion Pharmaceuticals

Bexion Pharmaceuticals is a privately – held biotech company focused on the development and commercialization of innovative cures for cancer. Bexion’s first – in – class biologic, BXQ – 350, has demonstrated selective tumor targeting with the potential for clinical efficacy in a broad range of cancers. In 2013 the NCI awarded Bexion a prestigious “Bridge Award” of $3MM to support testing of BXQ – 350 in the clinic. In February 2015, the FDA granted Bexion Orpha n Drug status for Saposin C, the active ingredient in its proprietary drug BXQ – 350 , for the potential treatment of glioblastoma multiforme (GBM), a type of brain cancer. In June 2015, Bexion won a Tibbett’s Award by the Small Business Administration for ex emplifying the very best in innovation.

Media Contact

Margaret van Gilse
859.757.1652 ●
mvangilse@bexionpharma.com

2018-10-29T23:45:09+00:00 October 18th, 2018|